Concord Biotech Limited — Results, 13-11-2025: Integrated Filing- Financial

Concord Biotech reported Q2 FY26 consolidated revenue of Rs 247.06 Cr, a 20.35% decline year-on-year, but a strong 21.11% sequential jump from Q1. Net profit for the quarter stood at Rs 63.06 Cr, down 34.13% YoY, with EPS at Rs 6.03, also down significantly. However, net profit surged 43.14% quarter-on-quarter. The decline in profitability YoY reflects lower revenue and higher employee benefit expenses. Strategically, the company is acquiring 100% of Celliimune Biotech and investing Rs 10 Cr in a solar project for its Limbasi Plant. Overall, the financial results show mixed momentum.